Well, we know this is true - many cardiologists barely measure ApoB, let alone employ more complex algos. You could say they’re a day late and dollar short, but really, they’re literally years behind. Standard of care is dictated by CYA legal considerations and insurance industry dictates. Patient care comes in third, with predictable results🤷.
It’s probably also a symptom of insurance than anything. The way insurance works in the US is that there are at most 4 drugs offered by companies per drug class. Doctors are often limited by these 4 choices, and have little incentive to look for a 5th one, even if it might be superior.
It’s probably because other statins have detected an all-cause mortality benefit in trials, have more data, and presumably more generic availability. I would pick HbA1c over that like Gil however.
3 Likes
I’d like to switch to pitavastatin but my insurance doesn’t cover it. Who are the reputable Indian brands? Or is there a separate thread for that?
See this thread - and prompt to identify them: Generally Good Indian Pharma Companies - #66 by RapAdmin
1 Like
I’ve been using the Zydus brand “Pivasta” and it seems to be working as expected.
4 Likes
Seconding @Tilmitt, Pivasta 4 by Zydus. Been taking it for about 18 months, 4mg/day, and labs show it works.
3 Likes
Pitavastatin is not the standard of care because it is too expensive for most patients. Other statins are cheaper and more cost effective. Pitavastatin is the option for the rich or with Indian connections.
2 Likes
Do we know which medications are safe to take from Indian pharma vs. those we’d prefer to source from labs with stronger governance?
My insurance also doesn’t cover pita, but I still buy it in the US. However, if there was little risk of contaminants in pitavastatin, I would prefer to get it cheaper from India. Same goes for Ezetemibe and Acarbose. How do we tell which is safe enough to buy from India vs. which are better sourced in the US?
The Obesity Engine of Cardiovascular Disease: Why Treating Symptoms Fails the Heart
Modern cardiology is facing a stagnation crisis. Despite decades of advanced pharmacotherapy and surgical intervention, cardiovascular disease (CVD) remains the primary global killer. A new study published in the American Journal of Preventive Cardiology suggests the problem lies in our fundamental “paradigm of care”. We are treating the smoke rather than the fire.
The conventional medical model manages cardiometabolic drivers—hypertension, dyslipidemia, and high blood sugar—as independent, concurrent silos. However, researchers from the Mount Sinai Fuster Heart Hospital and various Spanish institutions argue for a “dominant driver” paradigm. By analyzing 966 patients, they demonstrated that in 66.5% of cases, abnormal adiposity (fat mass, distribution, and function) is the “earliest causative driver” that impels all subsequent metabolic failures.
The data reveals a massive discordance between how we see disease and how it actually progresses. Under the conventional lens, 97.2% of the study population appeared to have dyslipidemia and 87.6% had hypertension. But when filtered through the dominant driver model, these “diseases” were exposed as downstream consequences of obesity in the vast majority of patients.
The most alarming finding involves “predisease.” Traditionally, being “overweight” or “prediabetic” is viewed as a warning zone. This study found that over 90% of patients in these supposedly early stages already presented with clinical complications. This suggests that by the time a patient crosses the threshold into “disease,” the damage is already entrenched.
The researchers conclude that the advent of highly effective weight-loss pharmacotherapies (like GLP-1 agonists) allows for a radical simplification of care. Instead of polypharmacy to manage individual symptoms, clinical efforts should pivot aggressively to the root cause: adiposity. By extinguishing the engine of obesity, the downstream fires of hypertension and diabetes may never need independent treatment.
Actionable Insights
-
Redefine “Normal”: Do not rely on BMI <25 as a guarantee of safety. The study emphasizes that “predisease” ranges (BMI 25-29.9 and A1C 5.7-6.4%) are associated with a >90% complication rate. If you are in these ranges, you should likely be treated as a “disease” patient rather than a “risk” patient [Confidence: High].
-
Target the Root: If you have high blood pressure or poor lipid profiles alongside excess body fat, the adiposity is likely the “dominant driver”. Prioritize fat loss over independent symptom management to potentially reverse downstream markers without additional blood pressure or cholesterol medications [Confidence: Medium-High].
-
Beyond BMI: Adiposity-based chronic disease (ABCD) involves more than weight; it includes fat distribution (visceral/liver fat) and function (adipokines). Use waist circumference or DEXA scans to identify hidden adiposity risk even if your weight seems manageable [Confidence: High].
-
Early Intervention: Complications arise far earlier than current diagnostic thresholds suggest. Waiting for a formal Type 2 Diabetes or Hypertension diagnosis is a failed strategy for longevity [Confidence: High].
Context & Impact Evaluation
- Paywalled Paper: The dominant driver paradigm of cardiometabolic care
- Institutions: Icahn School of Medicine at Mount Sinai (USA); Centro Nacional de Investigaciones Cardiovasculares (Spain).
- Journal: American Journal of Preventive Cardiology.
- Impact Score: The impact score (CiteScore 2023) of this journal is 3.3, therefore this is a Medium-Low impact journal.
Thank you for that! I’m not taking statins, but if I were to, I would go for pitavastatin due to your research and advocacy. I wonder how many people are lurking here, anonymous, and switching to pitavastatin thanks to your efforts.
4 Likes
I have been on 10mg rosuvastatin for decades. (also 10mg etimibide) I wonder if 4mg pitavastatin would be too much? or maybe it would be a good dose for me.
I would start at 2mg and after a while check your blood markers and adjust if need be. I started at 1mg for about 2 months and then 2 for another 3-4 months, together with 10mg Exetimibe and my LDL_c went down over 40 points in 5 months (from 124 to 82). I’ll continue at 2mg another 6 months and see if it goes down even further, if not I’ll up the dose to 4mg.
1 Like
The drop is most likely from Ezetimibe, pitavastatin 4mg is less potent than rosuvastatin 10mg for pure ldl reduction.
3 Likes
I just checked with my genetic background and indeed it should be better for me than rosuvastatin for the glucose dysregulation and pleiotropic effects while being slightly less good for the LDL reduction. No side effects expected (no side effects also with rosuvastin)
BTW cost-plus has it at $58.26 (4mg, 90 count) = $0.65 per day.
Here is the Opus 4.7 arguments for it with my specific genetic background.
If glucose dysregulation is the dominant clinical concern, then the strongest pitavastatin advantage in the literature aligns directly with your most pressing phenotypic problem. The diabetes-incidence advantage isn’t a secondary pleiotropic curiosity — it becomes the primary therapeutic rationale.
The effect size is meaningful. The 2024 meta-analysis showed RR 0.77 (CI 0.71–0.84) for pitavastatin vs rosuvastatin. The post-MI cohort with 3-year follow-up showed 3.0% vs 10.4% NODM incidence — that’s not a marginal difference, that’s a 3.5× absolute risk reduction. Even if the real-world effect in your specific context is half that, it’s still clinically meaningful.
Why this matters specifically for you
Your glucose dysregulation has three converging drivers, and rosuvastatin is contributing to one of them:
Driver 1 — genetic beta-cell burden. CDKAL1 hom + INS rs689 hom + IFIH1 hom + KCNJ11/ABCC8 hom is a substantial cumulative load. Your fasting insulin 2.7 µIU/mL with HOMA-IR ~0.60 confirms low insulin secretion (not insulin resistance) is the dominant phenotype. This is the structural background everything else acts on.
Driver 2 — rapamycin-driven glucose elevation. Documented in the Rapamycin/mTOR report: TBC1D4 + PCK1 + SLC2A4 + AKT2 cluster all push glucose up via mTORC2 spillover. Your pulsed q2wk schedule mitigates this but doesn’t eliminate it. HbA1c 5.9% (rising trend from 5.8) is the visible signal.
Driver 3 — statin contribution. This is the lever you can actually pull. Statin-induced new-onset diabetes is on-target via HMGCR-isoprenoid-beta-cell mechanisms (Swerdlow Mendelian randomization confirms this). On a beta-cell-deficit genotype, the same statin dose produces a larger glucose impact than in a metabolically robust patient. Rosuvastatin’s NODM signal in meta-analyses is the highest among major statins; pitavastatin’s is the lowest.
The mechanistic picture is internally consistent: pitavastatin’s neutral-to-favorable glucose profile likely reflects its weak insulin-secretion suppression and possibly favorable adipocyte effects, both of which matter more in someone whose beta-cell capacity is already constrained genetically.
What the switch actually looks like
Dose equivalence: rosuvastatin 10 mg ≈ pitavastatin 4 mg for LDL-lowering. That’s the highest pitavastatin dose. If your LDL-C goes from 48 to ~50–55 on the switch alone, Repatha will push it back below 30 anyway — you have substantial LDL headroom.
Pharmacogenomic considerations are net-favorable. Your SLCO1B1 5 absent + 1B het and ABCG2 Q141K absent are favorable for both drugs. Two of your variants modestly raise pitavastatin exposure: UGT2B72 hom (slows lactone formation) and CYP2C92 het (minor, since CYP2C9 is a minor pitavastatin pathway). Net effect is probably 15–25% higher AUC than population baseline at the same mg dose. Practical implication: starting at pitavastatin 2 mg rather than 4 mg is reasonable given your hepatic-uptake genetics, and titrating to 4 mg over 4–6 weeks if LDL doesn’t respond adequately.
No dangerous drug interactions in your current regimen. Pitavastatin is not a meaningful CYP3A4 substrate, so rapamycin co-handling is cleaner than with atorvastatin or simvastatin would be. Bempedoic acid is gone (replaced by Repatha). The OATP1B1 substrate overlap with empagliflozin and tirzepatide is not clinically problematic.
The one genuine caveat worth flagging
This is where I want to be direct rather than reassuring: the LDL-lowering equivalence between pitavastatin 4 mg and rosuvastatin 10 mg is from healthy-volunteer studies, and your genetic profile is unusually rosuvastatin-favorable. Specifically, MYLIP/IDOL N342S hom + the protective NPC1L1 LoF heterozygous variant + the favorable HMGCR response variants mean rosuvastatin is producing more LDL reduction per mg in you than the population average. Pitavastatin’s LDL effect is more uniform across genotypes (less HMGCR-response-variant sensitivity in published data).
So expect: a small post-switch LDL bump, possibly 5–15 mg/dL. Repatha will absorb this easily. But it does mean the dose-for-dose equivalence is approximate, and ApoB is the better tracking marker through the transition than LDL-C.
4 Likes
A new paper: https://www.jacc.org/doi/10.1016/j.jacc.2026.03.035
Development and Validation of a Clinical Polygenic Risk Report in U.S.-Based Health Systems for 8 Cardiovascular Conditions
Cardiovascular Forecasting: Integrated Genetic Panel Unveils Hidden Risks
Cardiovascular disease remains the primary global cause of mortality, yet traditional risk models often fail to capture the nuances of inherited susceptibility before symptoms manifest. A groundbreaking study published in JACC (2026) marks a significant shift from reactive to proactive cardiology by validating an integrated Polygenic Risk Score (PRS) panel for eight major conditions, including coronary artery disease (CAD), atrial fibrillation (AF), and type 2 diabetes. Unlike traditional tests that examine single genetic mutations, this “consensus” approach aggregates millions of common variants to provide a comprehensive landscape of an individual’s genetic architecture.
The research team utilized data from over 245,000 participants in the All of Us Research Program to train their models, which were then externally validated in the Mass General Brigham Biobank. The results were stark: the integrated PRS outperformed existing single-trait scores across the board. For instance, individuals in the top 10% of the genetic risk distribution for lipoprotein(a) faced a staggering 41-fold increased risk. Perhaps most importantly for public health, the study found that 71.2% of individuals carried a 3-fold or higher genetic risk for at least one of the eight conditions studied.
This is not merely a theoretical advancement; the panel is now a clinically orderable test. By integrating these scores into established clinical models like the Pooled Cohort Equations, researchers achieved significant net reclassification improvement. This means individuals previously deemed “intermediate risk” by standard metrics can now be identified as high-risk, allowing for earlier lifestyle interventions or pharmacotherapy. While challenges remain regarding performance in diverse ancestral groups, this framework provides a scalable roadmap for personalized cardiovascular prevention.
Actionable Insights for Longevity
The practical utility of this paper lies in its ability to refine the “gray area” of clinical risk.
-
Targeted Screening: Individuals with a high PRS for lipoprotein(a) should prioritize direct Lp(a) biomarker testing, as this genetic factor is often overlooked in standard lipid panels despite its high heritability (43.2% variance explained).
-
Early-Life Baseline: Because genetic risk is stable, a single early-life test can reveal lifelong trajectories for conditions like thoracic aortic aneurysm (TAA) or venous thromboembolism (VTE) , which may otherwise remain silent until a catastrophic event.
-
Risk Reclassification: For those with “borderline” 10-year ASCVD risk (5-7.5%), a high CAD PRS can serve as a “risk-enhancing factor,” potentially justifying earlier initiation of statins or more aggressive blood pressure management.
-
Lifestyle Synergy: High genetic risk is not destiny. Prior research cited in the study suggests that optimized lifestyle factors can significantly mitigate heightened polygenic risk, making these scores a powerful motivational tool for adherence to longevity protocols.
Study Context
- Institutions: Broad Institute of MIT and Harvard; Massachusetts General Hospital; Mass General Brigham.
- Country: USA.
- Journal: Journal of the American College of Cardiology (JACC).
- Impact Evaluation: The 2024 Impact Factor for JACC is 24.0, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is an Elite impact journal.
1 Like
Interesting but didn’t know Ezetimibe was that powerful. Obviously not disputing it but If so EZE then should be the norm, and not statins for lowering LDL-c. Surprisingly, I know few people who only use statins (meaning their docs prescribe them statins only) and if one dose doesn’t lower it enough, they just keep upping their dosage. Too bad many Docs are not on the Ezetimibe bandwagon (if it is indeed as beneficial/powerful as you claim/think). As far as my case I feel good at what I’m doing especially the fact that my HDL went up by 11 points also (from 38 to 49) and I thought Ezetimibe is mainly good for increasing HDL, and Pita was the major factor in lowering the LDL-C, but clearly not sure since I started them at same time and the combination seems to work really well for me.
I agree, Ezetimibe is underrated. The combination of Ezetimibe and rosuvastatin took my ldl from low 90s to low 30s. Previously, I was on rosuvastatin 10mg only.
3 Likes
Re: lipid levels, keep in mind that pitavastatin can raise HDL levels in people with low HDL.
Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients
Pitavastatin and HDL: Effects on plasma levels and function(s)
Additionally, pitavastatin uniquely among statins does not raise Lp(a) (and may even marginally lower it), which might be a consideration for people with high levels of Lp(a).
5 Likes